Jasper Card, a NYC-based financial services company, raised $34M in Series A funding.
The round, which encompasses $10M in funds announced before the company’s rebrand in 2020 from CreditStacks, was led by Benslie International Fund, with participation from 500 Startups, Gauss Ventures, Off The Grid Ventures, OurCrowd, and SIBF.
In addition to the funding, Mark Goines, Vice-Chair of Personal Capital, joined the Jasper Card Board of Directors that includes CardWorks Founder, Chairman, and CEO, Don Berman, Fraud Sciences Founder and CEO, Saar Wilf, Teva Pharmaceuticals’ former CFO, Eyal Desheh, and Industrialist Francisco Morphy.
The company intends to use the funds to grow its AI technology to further develop its underwriting model and introduce a new line of financial services.
Lucy’s weekly column in the The Financial Times that I subscribed over a decade ago always carried wit and charisma through which she dispelled the condescending talk of business executives, explaining that speaking clearly is way better: pointing to contrarian nature of such behaviour, used often to rather hide malpractice…
What looks like an evolution of Apple’s relationship with Marcus — may be an evolution of Apple e-commerce payment / button game, allowing participating banks to connect their credit to payments made online.
- Nominally, this looks like a push by GS’s Marcus to bolster the partnership that Apple has in the US, as the card function a) competes with other card offers people can link to Apple Pay b) has on-par loyalty / cash-back, that premium cards by leading providers like Chase provide…
Where I read this book several years ago, it still resonates clearly — amid new instability between now Russia and the US, cancelling Open Skies Treaty, investing in orbital missile systems or supersonic delivery mechanisms of nuclear weapons. …
A well planned and meticulously researched book that provides a bout of fresh air, despite decades spent on the subject and countless stories told in writing as well as cinematic optics, Dobbs holds one attention to the last page.
Especially poignant the story is in parallel to analysing recent Trump…
The funding is coming from Gauss Ventures and M&F Fund, among other unnamed investors. The startup has up to now opted to raise from individuals and smaller firms, CEO and founder Philip Belamant said in an interview, although that may change in future rounds as it looks both to bring…
Traydstream, a London based Fintech is delighted to announce the successful closure of its Series A funding round. The US $8m raised was led by Spearhead Capital in a round from institutional and private investors, including AFG Partners and several European Family Offices.
…
Traydstream’s scalable, secure and seamless solution has proven to be the answer for many institutions, and it is now live with clients across 4 continents and 17 markets.
May 24th, 2021
It has been barely 1 year when I wrote a short technical update for one of the projects I am involved — and many years now since I stopped sharing pensive thoughts on a range of subjects — from book updates to industry news items that impact my line of…
Source: Finextra, Square Press Release
“<Square> acquired Verse, a Spanish P2P payments app that allows customers to send and receive payments from friends and family instantly, safely, and free of charge.
We were drawn to Verse’s strong team, and they share a similar approach to us around inventing and learning to better serve customers. Verse will join the Cash App organization at Square, enabling the two teams to learn from one another as we provide them with additional support through Cash App technology and resources.”
Comment from Gauss Team:
It has been our privilege to add a token to the traction of Verse and we congratulate the team of Verse responsible for this milestone.
A new normal about employment initiatives, CAPEX investments, SaaS and machine-human interaction
My last flight was on February 26th, after, for almost 1 month, I battled with what looks like the virus that is now ravaging communities across the world.
The anti-bodies test is way off, making it impossible to second-guess the real cause of the malady, but the solace of isolation…
